MK-7110

Home
Ligands
MK-7110

GtoPdb Ligand ID: 11395

Synonyms: CD24-Fc [2] | CD24Fc

Compound class: Peptide or derivative

Comment: MK-7110 (originally OncoImmune's CD24Fc) is a synthetic protein that fuses the nonpolymorphic regions of CD24 (which is an agonist of Siglec-10) to the Fc region of human IgG1 [2]. It.is being investigated as a modulator of the innate immune system, originally as an intervention to ameliorate graft-versus-host disease in leukemia patients receiving stem cell transplants, or autoimmune diseases. The peptide's sequence was extracted from OncoImmune's patent US20130231464A1 [4]; the first 30 amino acids are the CD24 region and the remainder belong to the IgG1 Fc domain.

SARS-CoV-2 and COVID-19: Preclinical evidence in primate viral infection models showed that MK-7110 offered potential as a non-antiviral biological modality that could be applied to reduce inflammation in SARS-CoV-2 infection.

No information available.

No information available.

Summary of Clinical Use
OncoImmune originally intended MK-7110 (a.k.a. CD24Fc) to be used to treat GvHD and solid tumours [1]. It had progressed to Phase 3 for these indications. In response to the SARS-CoV-2 pandemic, Merck acquired OncoImmune and initiated trials of MK-7110 for severe COVID-19, to test the hypothesis that blocking CD24 might combat the excessive inflammation that can arise from this infection. Phase 1 evaluation in healthy participants revealed that MK-7110 suppressed the expression of multiple inflammatory cytokines, and the agent was subsequently progressed to Phase 3 in patients with severe COVID-19 inflammation. In March 2021, Merck were awaiting the outcome of an application to the FDA for Emergency Use Authorisation (EUA). The FDA responded by requesting a significant amount of additional research and data. As a result Merck announced in April 2021 that they would discontinue development of MK-7110 in COVID-19.

Summary of Clinical Use

OncoImmune originally intended MK-7110 (a.k.a. CD24Fc) to be used to treat GvHD and solid tumours [1]. It had progressed to Phase 3 for these indications. In response to the SARS-CoV-2 pandemic, Merck acquired OncoImmune and initiated trials of MK-7110 for severe COVID-19, to test the hypothesis that blocking CD24 might combat the excessive inflammation that can arise from this infection. Phase 1 evaluation in healthy participants revealed that MK-7110 suppressed the expression of multiple inflammatory cytokines, and the agent was subsequently progressed to Phase 3 in patients with severe COVID-19 inflammation. In March 2021, Merck were awaiting the outcome of an application to the FDA for Emergency Use Authorisation (EUA). The FDA responded by requesting a significant amount of additional research and data. As a result Merck announced in April 2021 that they would discontinue development of MK-7110 in COVID-19.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT04317040	CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment	Phase 3 Interventional	OncoImmune, Inc.
NCT04095858	CD24Fc for the Prevention of Acute GVHD Following Myeloablative HSCT	Phase 3 Interventional	OncoImmune, Inc.
NCT04060407	CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)	Phase 1/Phase 2 Interventional	OncoImmune, Inc.
NCT02650895	Safety Study of CD24Fc When Administered Intravenously in Healthy Adult Subjects	Phase 1 Interventional	OncoImmune, Inc.